Fortress Biotech Inc
NASDAQ:FBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Fortress Biotech Inc
Total Current Liabilities
Fortress Biotech Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
Total Current Liabilities
$54.1m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
8%
|
CAGR 10-Years
20%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
Fortress Biotech Inc
Glance View
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 173 full-time employees. The company went IPO on 2011-11-17. Fortress has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, and at its partner companies. Its product candidates span six market areas, including oncology, rare diseases and gene therapy. The firm's commercialized products include Ximino, Targadox, Exelderm, Ceracade, Luxamend and Accutane. Its late-stage product candidates include Intravenous (IV) Tramadol, CUTX-101, MB-107 and MB-207, Cosibelimab, CK-101, CAEL-101, Triplex and CEVA101. Its product candidates also consist of MB-102 (CD123 CAR T for BPDCN), MB-101 (IL13Ra2 CAR T for Glioblastoma), MB-104, MB-106, MB-103, AVTS-001, CK-103 and ConVax. The firm operates in two operating and reportable segments: Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
See Also
What is Fortress Biotech Inc's Total Current Liabilities?
Total Current Liabilities
54.1m
USD
Based on the financial report for Sep 30, 2025, Fortress Biotech Inc's Total Current Liabilities amounts to 54.1m USD.
What is Fortress Biotech Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
20%
Over the last year, the Total Current Liabilities growth was -23%. The average annual Total Current Liabilities growth rates for Fortress Biotech Inc have been -20% over the past three years , 8% over the past five years , and 20% over the past ten years .
